DNAnexus Adds NVIDIA NIM and CUDA-X Microservices to Precision Health Data Cloud to Accelerate Drug Discovery and Improve Patient Care

New Universal DeepVariant is one microservice compatible across multiple sequencing platforms and is designed to deliver more than 50x acceleration compared to CPU

MOUNTAIN VIEW, Calif. — DNAnexus, Inc., the provider of the Precision Health Data Cloud, today announced that it is integrating new NVIDIA NIM and CUDA-X microservices. These microservices are designed to allow researchers and bioinformaticians to easily integrate NVIDIA Parabricks tools into new and existing genomics workflows using the DNAnexus Precision Health Data Cloud to accelerate drug discovery and improve patient care.

The new suite of NVIDIA Parabricks NIM, an optimized inference microservice, and CUDA-X microservices includes optimized AI models and workflows with industry-standard APIs, or application programming interfaces, to serve as building blocks for creating and deploying cloud-native applications for genomics. The NVIDIA Parabricks microservices address the computational bottlenecks in genomics analysis, providing accelerated alignment and variant calling workflows. For example, the new Universal DeepVariant NIM delivers more than 50-fold speed improvement compared to the standard DeepVariant implementation on CPU. Additionally, it contains sequencer-specific models which are trained to achieve high accuracy on a variety of sequencing platforms, including short-read and long-read data. These production-grade microservices can be deployed through the NVIDIA AI Enterprise 5.0 software platform, now available directly through DNAnexus.

Today, DNAnexus has more than 48,000 registered users across 48 countries and actively manages and supports more than 105 petabytes of complex clinical genomic, proteomic, and other multi-omic datasets on behalf of a growing network of collaborators. Its comprehensive cloud platform meets the most rigorous industry standards for data quality, security, privacy, and regulatory compliance.

“DNAnexus is building the world’s largest and most trusted ecosystem of industry-leading data analysis tools that will shape the future of scientific discovery and precision health,” said Thomas Laur, CEO at DNAnexus. “This ongoing collaboration with NVIDIA will allow our customers to seamlessly apply the latest advances in AI to their specific workflows from anywhere at any time.”

“By working with providers like DNAnexus, NVIDIA is allowing more healthcare companies to create and deploy optimized models in biology and chemistry to build new solutions that will help drive the next wave of computer-aided drug discovery,” said Kimberly Powell, vice president of healthcare at NVIDIA.

To learn more about DNAnexus’ collaboration with NVIDIA, please visit https://www.dnanexus.com/partnerships/nvidia.

About DNAnexus

DNAnexus enables biomedical organizations to accelerate scientific discovery and improve patient care with the Precision Health Data Cloud. The company provides scientific innovators and healthcare professionals with the ability to manage, analyze, and collaborate on multi-omic, clinical, and real-world data to unlock insights. DNAnexus actively manages more than 105 petabytes of data on behalf of a growing network of collaborations with leading pharmaceutical, clinical diagnostic, academic research, biobank, and government organizations. Today, more than 45,000 users across 48 countries and over 130 enterprise customers are harnessing the full potential of their data with the scalable and secure Precision Health Data Cloud. DNAnexus is headquartered in Mountain View, Calif. For more information, visit www.dnanexus.com or follow @DNAnexus.

< | >